|
Eine Ebene nach oben |
Gruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 3
2019
Koletzko, Berthold; Godfrey, K. M.; Poston, Lucilla; Szajewska, Hania; van Goudoever, Johannes B.; de Waard, Marita; Brands, Brigitte; Grivell, Rosalie M.; Deussen, Andrea R.; Dodd, Jodie M.; Patro-Golab, Bernadeta; Zalewski, Bartlomiej M.; Alberdi, G.; Buonocore, G.; Campoy, C.; Demmelmair, H.; Desoye, G.; Diaz Gomez, M.; Escribano, J.; Geraghty, A.; Gil, A.; Hanson, M.; Inskip, H. M.; Larque, E.; Lassel, T.; Luque, V; Mader, S.; Manios, Y.; Mearin, L. M.; Oddy, W. H.; Reynolds, R. M.; Rueda, R.; Sherry, C.; Socha, P.; Taylor, P.; Van der Beek, E. M.; Weber, M.; Crespo-Escobar, P.; Gutser, M.; Kouwenhoven, S. M. P.; Calvo-Lerma, J. und Veldhorst, M.
(2019):
Nutrition During Pregnancy, Lactation and Early Childhood and its Implications for Maternal and Long-Term Child Health: The Early Nutrition Project Recommendations.
In: Annals of Nutrition and Metabolism, Bd. 74, Nr. 2: S. 93-106
2017
Lange, T.; Krahl, R.; Grünhagen, U. von; Al-Ali, H. K.; Schwarzer, A.; Jentsch-Ullrich, K.; Spohn, C.; Lakner, V.; Assmann, M.; Junghanss, C.; Pfirrmann, M.; Gil, A.; Hehlmann, R.; Deininger, M. und Niederwieser, D.
(2017):
Imatinib (IM) in combination with Hydroxyurea in patients with CML1st CP does not increase molecular response at 18 months compared to IM alone. Final results of the OSHO CML2004 study. NCT 02480608.
In: Oncology Research and Treatment, Bd. 40: S. 121-122
Lange, T.; Krahl, R.; Grünhagen, U. vom; Al-Ali, H. K.; Schwarzer, A.; Uhle, R.; Spohn, C.; Lakner, V.; Assmann, M.; Junghanss, C.; Pfirrmann, M.; Gil, A.; Hehlmann, R.; Deininger, M. und Niederwieser, D.
(2017):
Imatinib (im) 400mg in patients with cml1st cp results in a higher molecular response rate at 6 months compared to im/hydroxyurea. Final results of the cml2004 study. Nct 02480608.
In: Haematologica, Bd. 102: S. 729-730